/cloudfront-us-east-2.images.arcpublishing.com/reuters/BWRRND7NK5ORFONQ4YXBCQPDTU.jpg "GSK raises $1.24 bln from latest Haleon stake sale | Reuters")
GSK raises $1.24 bln from latest Haleon stake sale | Reuters
GSK Lifts Annual Outlook as Q3 Vaccine Sales Soar - TipRanks.com
Sell AstraZeneca, says UBS, which upgrades European rivals including GSK - MarketWatch
Glenmark Pharma & GSK Pharma: Top Stock Recommendation From Aditya Arora | ET Now - YouTube
GSK plans to sell stake in Unilever's India unit: Report
GSK (GSK) Stock Price, News & Info | The Motley Fool
Why GSK had to sell its Indian consumer health business
GSK plc (NYSE:GSK) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
GSK plc - Wikipedia
GSK slapped with 'sell' rating over long-term risks | LSE:GSK, NYSE:GSK
Is GSK a Strong Buy Right Now? | The Motley Fool
GSK: Glaxo SmithKline Share Price Target 2023, 2025, 2027, 2030 to 2050 - Sharedhan
GSK Consumer Healthcare's Horlicks sale could prove to be a sticky attraction for some | Mint
GlaxoSmithKline and Pfizer to Merge Consumer Health Units - The New York Times
GSK shares: Price analysis before buying or selling
GSK To Sell Poznań Manufacturing Site To Delpharm | Contract Pharma
With 83% ownership of the shares, GSK plc (LON:GSK) is heavily dominated by institutional owners - Simply Wall St News
GlaxoSmithKline reportedly looking to sell select antibiotic brands - PMLiVE
GSK Shares Gain on Analyst Upgrade, Price Target Boost - TipRanks.com
Should You Sell GlaxoSmithKline plc (LON:GSK) At This PE Ratio?
GSK Raises $1 Billion Selling Shares in Haleon Spinoff - Bloomberg
GlaxoSmithKline Stock Forecast | Is GlaxoSmithKline a Good Stock to Buy?
Pfizer Changes Its Mind, Will Sell Down Stake in GSK's Haleon Unit - Investing.com India
FTSE 100: GSK Reaches Settlement in Zantac Lawsuit | Markets Insider
Pfizer to sell stake in GSK consumer health joint venture after spinoff | HealthCare Middle East & Africa Magazine
A GSK Dividend Cut Is Imminent - Should I Sell GlaxoSmithKline? - TEV
GSK to sell 2.9% stake in former consumer healthcare business Haleon | Reuters
GlaxoSmithKline to leave landmark global HQ after split-up as consumer health business plots £120M new home | Fierce Pharma
